BioAtla BCAB 深 沪
等待开盘 09-09 09:30:00 美东时间
0.6112
+0.075
+13.92%
华盛通- 最 高0.62
- 今 开0.54
- 成交量 221.91万股
- 最 低 0.53
- 昨 收 0.5365
- 总市值 3570.51万
- 52周最高 2.525
- 市盈率 静 --
- 换手率 3.80%
- 52周最低 0.24
- 委 比 59.10%
- 总股本 5841.81万
- 历史最高 76.63
- 量 比 2.98
- 振 幅 16.78%
- 历史最低 0.24
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioAtla Highlights FDA Alignment On Phase 3 Ozuriftamab Vedotin Trial Design; Says Co Continues Preparations For Enabling Initiation Of Phase 3 Study; Co Maintains Previous Guidance
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3
09-08 20:07
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
BioAtla announced FDA alignment on the Phase 3 design for Ozuriftamab vedotin (Oz-V), including dosing and endpoints for potential accelerated approval. The company plans to initiate the Phase 3 study early next year with a strategic partner. Oz-V, a CAB-ADC targeting ROR2, showed promising results in HPV+ OPSCC with a 45% ORR and 11.6-month median OS in Phase 2 trials. FDA recommends a pivotal trial with 300 patients comparing Oz-V to standard t...
09-08 12:00
JMP Securities Downgrades BioAtla to Market Perform
JMP Securities analyst Reni J. Benjamin downgrades BioAtla (NASDAQ:BCAB) from Market Outperform to Market Perform.
08-13 22:15
跨国药企洞察｜默沙东终止康方2亿美元合作项目，跨国药企如何“优中选优”？
（来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们...
08-12 08:02
H.C. Wainwright Reaffirms Their Hold Rating on BioAtla (BCAB)
H.C. Wainwright analyst Arthur He CFA maintained a Hold rating on BioAtla today...
08-11 18:18
BioAtla Q2 EPS $(0.32) Misses $(0.29) Estimate
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 9.22 percent. This is a 27.27 percent increase over losses of $(0.44) per share from the same
08-08 04:09
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla reports progress on its clinical programs, including the Phase 1 dose-escalation study of BA3182 (a CAB-EpCAM x CAB-CD3 bispecific T-cell engager) and the Fast Track Designated Ozuriftamab vedotin (Oz-V) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). BA3182 has shown promising tumor reductions and prolonged progression-free intervals, with an expected Phase 1 data readout in the second half ...
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, plans to host a conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss its second-quarter 2025 financial results and business highlights. The webcast can be accessed at [this link](https://www.globenewswire.com/Tracker?data=RLJAQOCakPWTHB0UCPVd-O7q7MF8j9ZD5NrEL_6LnwrV...
08-04 12:00
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
BioAtla, Inc., a global clinical-stage biotechnology company, announced an oral presentation at the 2025 ESMO TAT Asia Meeting in Hong Kong. The presentation, titled "First-in-human phase I study of a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma," will be presented by Jennifer B. Brooke Valerin on July 18, 2025, at 15:59‒16:06 GMT+8. T...
07-17 12:00
